ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022
SARS-CoV-2 genomic surveillance in Malaysia: displacement of B.1.617.2 with AY lineages as the dominant Delta variants and the introduction of Omicron during the fourth epidemic wave.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Mapping the frontiers of genomic disease surveillance research in the ASEAN region: scientometric insights for precision public health and next-generation epidemic intelligence.Briefings in bioinformatics · 2026Article
- Neutralizing Antibody Response Dynamics in COVID-19: Insights from Healthy Vaccinees, Breakthrough Infections, and Critically Ill Patients.Tropical medicine and infectious disease · 2026Article
- Baseline cohort profile: clinical and molecular characterisation of SARS-CoV-2 infected patients recruited into a longitudinal COVID-19 cohort study (COVGEN) in Malaysia.BMC infectious diseases · 2026Article
- Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Malaysia: Epidemiological Data Update.Pulmonary therapy · 2026Article
- A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.Scientific reports · 2025Article
- The presence of neutralizing antibodies against omicron subvariants among a vaccinated cohort at one year after the first dose of vaccination in Malaysia.Scientific reports · 2025Article
- Genomic surveillance reveals COVID-19 outbreak clusters in a tertiary center in Malaysia: A cross-sectional study.IJID regions · 2025Article
- Detection of SARS-CoV-2 in bioaerosols and surface samples from healthcare facilities in Klang Valley, Malaysia.Scientific reports · 2025Article
- Antibody Response Following COVID-19 Vaccination in Malaysian Cancer Patients and Healthy Individuals.Cureus · 2024Article
- Insights into the Replication Kinetics Profiles of Malaysian SARS-CoV-2 Variant Alpha, Beta, Delta, and Omicron in Vero E6 Cell Line.International journal of molecular sciences · 2024Article
- Seroevidence of SARS-CoV-2 spillback to rodents in Sarawak, Malaysian Borneo.BMC veterinary research · 2024Article
- Unravelling the link between SARS-CoV-2 mutation frequencies, patient comorbidities, and structural dynamics.PloS one · 2024Article
- Timeline of SARS-CoV-2 Transmission in Sabah, Malaysia: Tracking the Molecular Evolution.Pathogens (Basel, Switzerland) · 2023Article
- Exploration of spatiotemporal heterogeneity and socio-demographic determinants on COVID-19 incidence rates in Sarawak, Malaysia.BMC public health · 2023Article
- Whole-genome sequencing of SARS-CoV-2 from residual viral RNA present on positive rapid antigen test kits for genomic surveillance.Western Pacific surveillance and response journal : WPSARArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study reported SARS-CoV-2 whole genome sequencing results from June 2021 to January 2022 from seven genome sequencing centers in Malaysia as part of the national surveillance program.
methodsCOVID-19 samples that tested positive by reverse transcription polymerase chain reaction and with cycle threshold values <30 were obtained throughout Malaysia. Sequencing of SARS-CoV-2 complete genomes was performed using Illumina, Oxford Nanopore, or Ion Torrent platforms. A total of 6163 SARS-CoV-2 complete genome sequences were generated over the surveillance period. All sequences were submitted to the Global Initiative on Sharing All Influenza Data database.
resultsFrom June 2021 to January 2022, Malaysia experienced the fourth wave of COVID-19 dominated by the Delta variant of concern, including the original B.1.617.2 lineage and descendant AY lineages. The B.1.617.2 lineage was identified as the early dominant circulating strain throughout the country but over time, was displaced by AY.59 and AY.79 lineages in Peninsular (west) Malaysia, and the AY.23 lineage in east Malaysia. In December 2021, pilgrims returning from Saudi Arabia facilitated the introduction and spread of the BA.1 lineage (Omicron variant of concern) in the country.
conclusionThe changing trends of circulating SARS-CoV-2 lineages were identified, with differences observed between west and east Malaysia. This initiative highlighted the importance of leveraging research expertise in the country to facilitate pandemic response and preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.